Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies to simplify how people with diabetes manage their condition.
The two companies will take an innovative approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with insulin dosing information for future smart pens, insulin titration apps and cloud software.
Gustavo Pesquin, Senior Vice President Global Diabetes and Cardiovascular Franchise at Sanofi, said: “By partnering with Abbott, we are a step closer to realizing our connected ecosystem, which would help improve control and the quality of life decision cycle for patients through individualized glycemic management of diabetes.”
The non-exclusive collaboration will initially enable data sharing, at the consent of the user, between Abbott’s FreeStyle Libre mobile app and cloud software and Sanofi’s connected insulin pens, apps and cloud software that are currently in development.
This data sharing will enable both people with diabetes and their doctors to make better informed treatment decisions around medication, nutrition and lifestyle.
Jared Watkin, Senior Vice President of Diabetes Care at Abbott, said: “Building a digital ecosystem around FreeStyle Libre simplifies the user experience by consolidating how people get their data – both through offering Abbott’s digital health tools and by working with other diabetes and technology leaders.”
Sanofi is currently working to provide connected pens, apps and cloud software that will be compatible with the FreeStyle Libre system and its compatible digital health tools.
The two companies aim to bring this to people with diabetes within the next few years, pending local regulatory approvals.